Scientists have identified a unique molecule in the blood of Burmese pythons that could revolutionize obesity treatment. Pythons are known for consuming massive meals—sometimes exceeding their own body weight—and then surviving for months without eating. This metabolic feat is now linked to a specific metabolite, dubbed pTOS, which researchers believe could form the basis of a new class of appetite-suppressant drugs.
The Python’s Metabolic Secret
Burmese pythons exhibit extreme physiological changes when feeding. Their hearts grow by 25%, and their metabolism speeds up 4,000 times to process large meals. Afterward, they enter prolonged periods of fasting. Researchers at Stanford University and the University of Colorado Boulder sought to understand the biochemical mechanisms behind these shifts, focusing on metabolites present in the snakes’ blood before and after feeding.
The study examined young pythons (weighing 1.5–2.5 kg) fasted for 28 days before being given a meal equivalent to 25% of their body weight. Analysis revealed over 200 molecules increasing post-feeding, with pTOS spiking by more than 1,000-fold. This molecule is produced by gut bacteria and exists in trace amounts in human urine.
Appetite Suppression in Mice
Initial tests focused on whether pTOS affected the snake’s organ growth or energy expenditure. However, administering the molecule to obese mice yielded a surprising result: the mice ate significantly less. After 28 days, mice treated with pTOS lost 9% of their body weight.
This is significant because current obesity drugs like Wegovy rely on slowing stomach emptying, which can cause nausea and digestive issues. pTOS, instead, appears to act directly on the hypothalamus—the brain region regulating appetite—potentially offering a cleaner, more targeted approach.
A Safer Alternative?
The team believes that because pTOS is a naturally occurring human metabolite, it may prove safer than synthetic drugs. Further research is crucial to confirm its clinical viability, but the initial findings suggest a novel pathway for treating obesity.
“We’ve basically discovered an appetite suppressant that works in mice without some of the side-effects that GLP-1 drugs have,” explains Professor Leslie Leinwand.
The study highlights the potential for learning from extreme adaptations in the natural world. The python’s unique metabolic system offers valuable insights into appetite regulation and could lead to a new generation of obesity treatments.
